1H-咪唑并[1,2-a]咪唑 | 251-91-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1H-咪唑并[1,2-a]咪唑
• 英文名称: 1H-imidazo[1,2-a]imidazole
• 英文别名: imidazo[1,2-a]imidazole
• CAS: 251-91-2
• 化学式: C₅H₅N₃
• mdl: MFCD00228846
• 分子量: 107.115
• InChiKey: WWWMWOWPAWAERK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  33.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1H-咪唑并[1,2-a]咪唑 在 盐酸 作用下， 以 四氢呋喃 为溶剂， 反应 6.0h， 生成 (2-Imidazo[1,2-a]imidazol-1-yl-1-phosphono-ethyl)-phosphonic acid
  参考文献：
  名称：

  Studies on Novel Bone Resorption Inhibitors. II. Synthesis and Pharmacological Activities of Fused Aza-heteroarylbisphosphonate Derivatives.

  摘要：

  我们合成了两个新系列的融合杂己基双膦酸盐（5、8），它们在结构上与incadronate（YM175）和相关化合物有很大不同，并利用甲状旁腺激素（PTH）诱导的大鼠高钙血症模型（PIH 模型）对它们的抗骨吸收活性进行了评估。在这些化合物中，有几种表现出比帕米膦酸钠更强的抗骨吸收活性。其中，[1-羟基-2-（咪唑并[1，2-α]吡啶-3-基）亚乙基]双膦酸（5b，minodronate）不仅在 PIH 模型中，而且在大鼠固定骨萎缩模型（DA 模型）中的活性都比帕米膦酸高出 100 倍，因此被选中用于临床开发。本文讨论了这些新系列双膦酸盐的结构-活性关系。

  DOI：

  10.1248/cpb.46.1703
• 作为产物：
  描述：

  1-(2,2-二乙氧基乙基)-2-氨基咪唑 在 盐酸 、 水 作用下， 以81 %的产率得到1H-咪唑并[1,2-a]咪唑
  参考文献：
  名称：

  NOVEL ALPK1 INHIBITORS

  摘要：

  The disclosure is directed to novel ALPK1 inhibitors having the Formula (I), or a pharmaceutical acceptable salt, a stereoisomer, a tautomer, a stable isotopic variant, a prodrug, or a crystal form thereof. The disclosure is also directed to pharmaceutical composition comprising the novel ALPK1 inhibitors, and use thereof in treating inflammation related diseases, such as ROSAH syndrome, inflammatory bowel disease (IBD), NASH, gout, diabetes, chronic kidney disease, pancreatitis, Kawasaki disease, inflammatory skin diseases and neurodegenerative diseases including the Alzheimer's disease.

  公开号：

  WO2024153225A1

文献信息

• Studies on Novel Bone Resorption Inhibitors. II. Synthesis and Pharmacological Activities of Fused Aza-heteroarylbisphosphonate Derivatives.
  作者：Makoto TAKEUCHI、Shunichi SAKAMOTO、Kousei KAWAMUKI、Hiroyuki KURIHARA、Hideaki NAKAHARA、Yasuo ISOMURA

  DOI：10.1248/cpb.46.1703

  日期：——

  Two new series of fused aza-heteroarylbisphosphonates (5, 8), which are structurally quite different from incadronate (YM175), and related compounds were synthesized and evaluated for antiresorptive activity using a parathyroid hormone (PTH)-induced hypercalcemia model in rats (PIH model). Among these compounds, several exhibited more potent antiresorptive activity than pamidronate. In particular, [1-hydroxy-2-(imidazo[1, 2-α]pyridin-3-yl)ethylidene]bisphosphonic acid (5b, minodronate) was 100-fold more potent than pamidronate in not only the PIH model, but also in an immobilization bone atrophy model in rats (DA model), and was selected for clinical development. The structure-activity relationships in these new series of bisphosphonates are discussed.

  我们合成了两个新系列的融合杂己基双膦酸盐（5、8），它们在结构上与incadronate（YM175）和相关化合物有很大不同，并利用甲状旁腺激素（PTH）诱导的大鼠高钙血症模型（PIH 模型）对它们的抗骨吸收活性进行了评估。在这些化合物中，有几种表现出比帕米膦酸钠更强的抗骨吸收活性。其中，[1-羟基-2-（咪唑并[1，2-α]吡啶-3-基）亚乙基]双膦酸（5b，minodronate）不仅在 PIH 模型中，而且在大鼠固定骨萎缩模型（DA 模型）中的活性都比帕米膦酸高出 100 倍，因此被选中用于临床开发。本文讨论了这些新系列双膦酸盐的结构-活性关系。
• NOVEL ALPK1 INHIBITORS
  申请人：[en]PYROTECH (BEIJING) BIOTECHNOLOGY CO., LTD.

  公开号：WO2024153225A1

  公开（公告）日：2024-07-25

  The disclosure is directed to novel ALPK1 inhibitors having the Formula (I), or a pharmaceutical acceptable salt, a stereoisomer, a tautomer, a stable isotopic variant, a prodrug, or a crystal form thereof. The disclosure is also directed to pharmaceutical composition comprising the novel ALPK1 inhibitors, and use thereof in treating inflammation related diseases, such as ROSAH syndrome, inflammatory bowel disease (IBD), NASH, gout, diabetes, chronic kidney disease, pancreatitis, Kawasaki disease, inflammatory skin diseases and neurodegenerative diseases including the Alzheimer's disease.